CIDP Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Chronic Inflammatory Demyelinating Polyneuropathy pipeline constitutes 2+ key companies continuously working towards developing 4+ Chronic Inflammatory Demyelinating Polyneuropathy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Chronic Inflammatory Demyelinating Polyneuropathy Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Chronic Inflammatory Demyelinating Polyneuropathy Market.

The Chronic Inflammatory Demyelinating Polyneuropathy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Chronic Inflammatory Demyelinating Polyneuropathy Pipeline Report: https://www.delveinsight.com/sample-request/chronic-inflammatory-demyelinating-polyneuropathy-cidp-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Chronic Inflammatory Demyelinating Polyneuropathy treatment therapies with a considerable amount of success over the years.
• Chronic Inflammatory Demyelinating Polyneuropathy companies working in the treatment market are Takeda, Argenx, Sanofi, Janssen Research and Development, Immunovant Sciences GmbH, HanAll Pharma, Roivant Sciences, Shire, Argenx, Sanofi, Nihon Pharmaceutical, Immunovant Sciences, Octapharma, CSL Behring, Janssen Research, Novartis, Biogen, UCB Biopharma, Takeda, MedDay Pharmaceuticals, Teijin Pharma, Pfizer, Octapharma, Momenta Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, Kedrion, Grifols, Bio Products Laboratory, Baxter, GeNeuro Pharmaceuticals, and others, are developing therapies for the Chronic Inflammatory Demyelinating Polyneuropathy treatment
• Emerging Chronic Inflammatory Demyelinating Polyneuropathy therapies in the different phases of clinical trials are- HYQVIA (Immune Globulin Infusion 10% [Human] with Recombinant Human Hyaluronidase), VYVGART HYTRULO (Efgartigimod Alfa and Hyaluronidase-Qvfc), GAMMAGARD LIQUID/KIOVIG (Immune Globulin Infusion [Human] 10% Solution), Riliprubart (SAR445088), Nipocalimab, Batoclimab (HL161), Efgartigimod, SAR445088, NPB-01, Batoclimab, Panzyga, IgPro20, Nipocalimab, Fingolimod, Interferon Beta-1a, Rozanolixizumab, TAK-771, MD1003, and others are expected to have a significant impact on the Chronic Inflammatory Demyelinating Polyneuropathy market in the coming years.
• In June 2025, Japan's Ministry of Health, Labour and Welfare (MHLW) has awarded orphan drug designation to riliprubart, a monoclonal antibody that specifically inhibits activated C1s in the classical complement pathway for patients with chronic inflammatory demyelinating polyneuropathy (CIDP). Despite existing treatments, many CIDP patients continue to experience residual symptoms such as weakness, numbness, and fatigue, which can result in long-term complications and reduced quality of life. Around 30% of CIDP patients do not respond to standard therapies. The MHLW grants orphan drug status to medicines targeting rare diseases or conditions with unmet medical needs. Currently, approximately 4,000 individuals in Japan are diagnosed with CIDP.
• In June 2025, Amsterdam, the Netherlands - argenx SE (Euronext & Nasdaq: ARGX), a global immunology company focused on improving outcomes for individuals with severe autoimmune disorders, announced that the European Commission (EC) has approved VYVGART® (efgartigimod alfa) 1000 mg for subcutaneous (SC) injection as a standalone therapy for adult patients with progressive or relapsing active chronic inflammatory demyelinating polyneuropathy (CIDP) following prior corticosteroid or immunoglobulin treatment. VYVGART SC is available in vials or prefilled syringes and can be administered by patients, caregivers, or healthcare professionals. The treatment begins with a weekly dosing schedule, which can be adjusted to every other week based on clinical assessment.
• In May 2025, Nuvig Therapeutics, Inc. ("Nuvig"), a private biotechnology firm focused on developing innovative immunomodulatory therapies for inflammatory autoimmune diseases, announced that the first patient has been treated in its Phase 2 clinical trial assessing NVG-2089 in individuals with chronic inflammatory demyelinating polyneuropathy (CIDP). The company also revealed plans to present Phase 1 study results of NVG-2089 in healthy volunteers at the 2025 Peripheral Nerve Society (PNS) Annual Meeting.
• In January 2025, A recent study published in Annals of Clinical and Translational Neurology reported that, based on a retrospective cohort analysis in China, a simplified regimen using low-dose rituximab (Rituxan; Genentech/Biogen) demonstrated better efficacy and safety compared to standard therapy in treating patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).

Chronic Inflammatory Demyelinating Polyneuropathy Overview
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a rare autoimmune disorder that affects the peripheral nerves, causing inflammation and damage to the myelin sheath-the protective covering of nerves. This leads to progressive weakness, numbness, and impaired sensory function in the arms and legs. CIDP can develop over weeks to months and may result in difficulty walking, reduced reflexes, and fatigue. While the exact cause is unknown, the immune system mistakenly attacks the nerves. Treatment typically involves immunotherapy, such as corticosteroids, intravenous immunoglobulin (IVIg), or plasma exchange, to reduce inflammation and slow disease progression.

Get a Free Sample PDF Report to know more about Chronic Inflammatory Demyelinating Polyneuropathy Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/chronic-inflammatory-demyelinating-polyneuropathy-cidp-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Chronic Inflammatory Demyelinating Polyneuropathy Drugs Under Different Phases of Clinical Development Include:
• HYQVIA (Immune Globulin Infusion 10% [Human] with Recombinant Human Hyaluronidase): Takeda
• VYVGART HYTRULO (Efgartigimod Alfa and Hyaluronidase-Qvfc): Argenx
• GAMMAGARD LIQUID/KIOVIG (Immune Globulin Infusion [Human] 10% Solution): Takeda
• Riliprubart (SAR445088): Sanofi
• Nipocalimab: Janssen Research and Development
• Batoclimab (HL161): Immunovant Sciences GmbH/HanAll Pharma/Roivant Sciences
• HyQvia: Shire
• Efgartigimod: Argenx
• SAR445088: Sanofi
• NPB-01: Nihon Pharmaceutical
• Batoclimab: Immunovant Sciences
• Panzyga: Octapharma
• IgPro20: CSL Behring
• Nipocalimab: Janssen Research
• Fingolimod: Novartis
• Interferon Beta-1a: Biogen
• Rozanolixizumab: UCB Biopharma SRL
• TAK-771: Takeda
• MD1003: MedDay Pharmaceuticals

Chronic Inflammatory Demyelinating Polyneuropathy Route of Administration
Chronic Inflammatory Demyelinating Polyneuropathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Chronic Inflammatory Demyelinating Polyneuropathy Molecule Type
Chronic Inflammatory Demyelinating Polyneuropathy Products have been categorized under various Molecule types, such as
• Monoclonal antibody
• Small molecule
• Peptide

Chronic Inflammatory Demyelinating Polyneuropathy Pipeline Therapeutics Assessment
• Chronic Inflammatory Demyelinating Polyneuropathy Assessment by Product Type
• Chronic Inflammatory Demyelinating Polyneuropathy By Stage and Product Type
• Chronic Inflammatory Demyelinating Polyneuropathy Assessment by Route of Administration
• Chronic Inflammatory Demyelinating Polyneuropathy By Stage and Route of Administration
• Chronic Inflammatory Demyelinating Polyneuropathy Assessment by Molecule Type
• Chronic Inflammatory Demyelinating Polyneuropathy by Stage and Molecule Type

DelveInsight's Chronic Inflammatory Demyelinating Polyneuropathy Report covers around 4+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Chronic Inflammatory Demyelinating Polyneuropathy product details are provided in the report. Download the Chronic Inflammatory Demyelinating Polyneuropathy pipeline report to learn more about the emerging Chronic Inflammatory Demyelinating Polyneuropathy therapies at:
https://www.delveinsight.com/sample-request/chronic-inflammatory-demyelinating-polyneuropathy-cidp-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics Market include:
Key companies developing therapies for Chronic Inflammatory Demyelinating Polyneuropathy are - Takeda, Octapharma, Immupharma, Argenx, Zai Lab, Johnson & Johnson, UCB, Sanofi, Zenyaku Kogyo Co, Grifols, Biotest, Biocon, KM Biologics, and others.

Chronic Inflammatory Demyelinating Polyneuropathy Pipeline Analysis:
The Chronic Inflammatory Demyelinating Polyneuropathy pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Inflammatory Demyelinating Polyneuropathy Treatment.
• Chronic Inflammatory Demyelinating Polyneuropathy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Chronic Inflammatory Demyelinating Polyneuropathy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Inflammatory Demyelinating Polyneuropathy market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Chronic Inflammatory Demyelinating Polyneuropathy drugs and therapies-
https://www.delveinsight.com/sample-request/chronic-inflammatory-demyelinating-polyneuropathy-cidp-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Chronic Inflammatory Demyelinating Polyneuropathy Pipeline Market Drivers
• Growing research for the treatment of CIDP, increase in the healthcare expenditure are some of the important factors that are fueling the Chronic Inflammatory Demyelinating Polyneuropathy Market.

Chronic Inflammatory Demyelinating Polyneuropathy Pipeline Market Barriers
• However, high cost of treatment and related adverse events, lack of awareness of guidelines and other factors are creating obstacles in the Chronic Inflammatory Demyelinating Polyneuropathy Market growth.

Scope of Chronic Inflammatory Demyelinating Polyneuropathy Pipeline Drug Insight
• Coverage: Global
• Key Chronic Inflammatory Demyelinating Polyneuropathy Companies: Takeda, Argenx, Sanofi, Janssen Research and Development, Immunovant Sciences GmbH, HanAll Pharma, Roivant Sciences, Shire, Argenx, Sanofi, Nihon Pharmaceutical, Immunovant Sciences, Octapharma, CSL Behring, Janssen Research, Novartis, Biogen, UCB Biopharma, Takeda, MedDay Pharmaceuticals, Teijin Pharma, Pfizer, Octapharma, Momenta Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, Kedrion, Grifols, Bio Products Laboratory, Baxter, GeNeuro Pharmaceuticals, and others
• Key Chronic Inflammatory Demyelinating Polyneuropathy Therapies: HYQVIA (Immune Globulin Infusion 10% [Human] with Recombinant Human Hyaluronidase), VYVGART HYTRULO (Efgartigimod Alfa and Hyaluronidase-Qvfc), GAMMAGARD LIQUID/KIOVIG (Immune Globulin Infusion [Human] 10% Solution), Riliprubart (SAR445088), Nipocalimab, Batoclimab (HL161), Efgartigimod, SAR445088, NPB-01, Batoclimab, Panzyga, IgPro20, Nipocalimab, Fingolimod, Interferon Beta-1a, Rozanolixizumab, TAK-771, MD1003, and others
• Chronic Inflammatory Demyelinating Polyneuropathy Therapeutic Assessment: Chronic Inflammatory Demyelinating Polyneuropathy current marketed and Chronic Inflammatory Demyelinating Polyneuropathy emerging therapies
• Chronic Inflammatory Demyelinating Polyneuropathy Market Dynamics: Chronic Inflammatory Demyelinating Polyneuropathy market drivers and Chronic Inflammatory Demyelinating Polyneuropathy market barriers

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.